Bioage Labs now intends to set up an internal laboratory to experiment with different compounds, while building out its team.
The firm announced a 14 percent drop year-over-year in fourth quarter revenues and plans to reduce personnel and other costs to support development of a precision drug it has licensed.
The Cambridge, Massachusetts-based precision medicine firm hopes to translate molecular information into therapies for chronic kidney diseases.
The researchers identified new combinations of mutated genes and drugs that could provide the platform for future cancer therapies.
Backed by $12 million from a recent Series A financing and a strategic partnership with Thermo Fisher Scientific, the Ann Arbor, Michigan-based firm plans to sequence the tumors of 100,000 advanced cancer patients over three years.
Cyclica will soon begin testing a commercial version of its services software this summer ahead of a full launch planned for next year.
Portable's mobile app allows patients to capture genotype, phenotype, and other data, and potentially profit from sharing it with interested third parties.
Using Luminex's FlexMap detector, the method allows quantification of cells in a mixture of up to hundreds of individual cells lines treated with drugs in vitro.
Under the terms of the agreement, Insilico Medicine will integrate unspecified data assets and the staff of Belgian bioinformatics company InSilico Screen.
The Los Angeles Times reports that a case of the novel coronavirus making people ill in China has been reported in the US.
A bipartisan group of senators has introduced a bill seeking increased funding for certain fields, including synthetic biology, ScienceInsider reports.
Discover magazine writes that paleoproteomics is increasing being used in archaeology, paleoanthropology, and paleontology, including a recent study of a 6,000-year-old ring.
In Nucleic Acids Research this week: mutagenic effects of ultraviolet "A" light, post-transcription effects of synonymous mutations, and more.